Inhibition of breast and brain cancer cell growth by BCCIPα, an evolutionarily conserved nuclear protein that interacts with BRCA2

被引:80
|
作者
Liu, JM
Yuan, Y
Huan, J
Shen, ZY
机构
[1] Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA
[2] Univ Illinois, Coll Med, Grad Program Mol Genet, Chicago, IL 60607 USA
关键词
BRCA2; calcium-binding protein; BCCIP;
D O I
10.1038/sj.onc.1204098
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
BRCA2 is a tumor suppressor gene involved in mammary tumorigenesis, Although important functions have been assigned to a few conserved domains of BRCA2, little is known about the longest internal conserved domain encoded by exons 14-24.,We identified a novel protein, designated BCCIP alpha, that interacts with part of the internal conserved region of human BRCA2, Human BCCIP represents a family of proteins that are evolutionarily conserved, and contain three distinct domains: an N-terminus acidic domain (NAD) of 30-60 amino acids, an internal conserved domain (ICD) of 180-220 amino acids, and a C-terminus variable domain (CVD) of 30-60 amino acids, The N-terminal half of the human BCCIP ICD shares moderate homology with regions of calmodulin and ill-calpain, suggesting that BCCIP may also bind Ca. Human cells express both a longer, BCCIP alpha, and a shorter, BCCIP beta, form of the protein, which differ in their CVD, BCCIP is a nuclear protein highly expressed in testis, Although BCCIP beta expression is relatively consistent in cancer cells, the expression of BCCIP alpha varies in cancer cell Lines. The BCCIP alpha gene is located at chromosome 10q25.3-26.2, a region frequently altered in brain and other cancers. Furthermore, expression of BCCIP alpha inhibits breast and brain cancer cell growth,but fails to inhibit HT1080 cells and a non-transformed human skin fibroblast, These results suggest that BCCIP alpha is an important cofactor for BRCA2 in tumor suppression.
引用
收藏
页码:336 / 345
页数:10
相关论文
共 50 条
  • [31] Novel BRCA2-Interacting Protein, LIMD1, Is Essential for the Centrosome Localization of BRCA2 in Esophageal Cancer Cell
    Hou, Xiaobin
    Li, Tinghui
    Ren, Zhipeng
    Liu, Yang
    ONCOLOGY RESEARCH, 2016, 24 (04) : 247 - 253
  • [32] Transcriptional signature of lymphoblastoid cell lines of BRCA1, BRCA2 and non-BRCA1/2 high risk breast cancer families
    Pouliot, Marie-Christine
    Kothari, Charu
    Joly-Beauparlant, Charles
    Labrie, Yvan
    Ouellette, Genevieve
    Simard, Jacques
    Droit, Arnaud
    Durocher, Francine
    ONCOTARGET, 2017, 8 (45) : 78691 - 78712
  • [33] The beta-isoform of the BRCA2 and CDKN1A(p21)-interacting protein (BCCIP) stabilizes nuclear RPL23/uL14
    Wyler, Emanuel
    Wandrey, Franziska
    Badertscher, Lukas
    Montellese, Christian
    Alper, Daniel
    Kutay, Ulrike
    FEBS LETTERS, 2014, 588 (20) : 3685 - 3691
  • [34] Functional interaction of the Fanconi Anemia protein, FANCD2 with the breast cancer susceptibility protein, BRCA2, in damage chromatin.
    Wang, XZ
    Andreassen, P
    D'Andrea, AD
    BLOOD, 2003, 102 (11) : 159A - 159A
  • [35] Evaluation of BRCA1 and BRCA2 Protein Dysfunction in Breast Cancer Cells among Women in Osun State, Southwest Nigeria.
    Iyiola, S.
    Komolafe, A.
    Samuel, A.
    Onifade, J. A.
    Enweani, I.
    Ngokere, A.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2020, 154 : S118 - S119
  • [36] Epidemiological and ES cell-based functional evaluation of BRCA2 variants identified in families with breast cancer
    Sullivan, Teresa
    Thirthagiri, Eswary
    Chong, Chan-Eng
    Stauffer, Stacey
    Reid, Susan
    Southon, Eileen
    Hassan, Tiara
    Ravichandran, Aravind
    Wijaya, Eldarina
    Lim, Joanna
    Taib, Nur Aishah Mohd
    Fadzli, Farhana
    Yip, Cheng Har
    Hartman, Mikael
    Li, Jingmei
    van Dam, Rob M.
    North, Susan L.
    Das, Ranabir
    Easton, Douglas F.
    Biswas, Kajal
    Teo, Soo-Hwang
    Sharan, Shyam K.
    HUMAN MUTATION, 2021, 42 (02) : 200 - 212
  • [37] BRCA1 and BRCA2 5′ noncoding region variants identified in breast cancer patients alter promoter activity and protein binding
    Burke, Leslie J.
    Sevcik, Jan
    Gambino, Gaetana
    Tudini, Emma
    Mucaki, Eliseos J.
    Shirley, Ben C.
    Whiley, Phillip
    Parsons, Michael T.
    De Leeneer, Kim
    Gutierrez-Enriquez, Sara
    Santamarina, Marta
    Caputo, Sandrine M.
    dos Santos, Elizabeth Santana
    Soukupova, Jana
    Janatova, Marketa
    Zemankova, Petra
    Lhotova, Klara
    Stolarova, Lenka
    Borecka, Mariana
    Moles-Fernandez, Alejandro
    Manoukian, Siranoush
    Bonanni, Bernardo
    Edwards, Stacey L.
    Blok, Marinus J.
    Hansen, Thomas van Overeem
    Rossing, Maria
    Diez, Orland
    Vega, Ana
    Claes, Kathleen B. M.
    Goldgar, David E.
    Rouleau, Etienne
    Radice, Paolo
    Peterlongo, Paolo
    Rogan, Peter K.
    Caligo, Maria
    Spurdle, Amanda B.
    Brown, Melissa A.
    HUMAN MUTATION, 2018, 39 (12) : 2025 - 2039
  • [38] PCID2 Facilitates the Nuclear Export, but not the Centrosomal Localization, of BRCA2 in Hs578T Breast Cancer Cells
    Pollio, Noah C.
    Resendes, Karen K.
    FASEB JOURNAL, 2022, 36
  • [39] Durable Clinical Benefit of Pertuzumab in a Young Patient with BRCA2 Mutation and HER2-Overexpressing Breast Cancer Involving the Brain
    Koumarianou, Anna
    Kontopoulou, Christina
    Kouloulias, Vassilis
    Tsionou, Christina
    CASE REPORTS IN ONCOLOGICAL MEDICINE, 2016, 2016
  • [40] Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers
    Susan L Neuhausen
    Sean Brummel
    Yuan Chun Ding
    Christian F Singer
    Georg Pfeiler
    Henry T Lynch
    Katherine L Nathanson
    Timothy R Rebbeck
    Judy E Garber
    Fergus Couch
    Jeffrey Weitzel
    Steven A Narod
    Patricia A Ganz
    Mary B Daly
    Andrew K Godwin
    Claudine Isaacs
    Olufunmilayo I Olopade
    Gail Tomlinson
    Wendy S Rubinstein
    Nadine Tung
    Joanne L Blum
    Daniel L Gillen
    Breast Cancer Research, 11